{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T11:01:47Z","timestamp":1780830107836,"version":"3.54.1"},"reference-count":0,"publisher":"Komitet Redakcyjno - Wydawniczy Polskiego Towarzystwa Psychiatrycznego","issue":"2","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychiatr Pol"],"published-print":{"date-parts":[[2026,4,30]]},"abstract":"<jats:sec>\n                    <jats:title>Cel pracy<\/jats:title>\n                    <jats:p>Celem pracy by\u0142o por\u00f3wnanie wyst\u0119powania objaw\u00f3w depresyjnych pomi\u0119dzy grup\u0105 chorych na MPN (nadp\u0142ytkowo\u015b\u0107 samoistn\u0105, czerwienic\u0119 prawdziw\u0105 oraz samoistne w\u0142\u00f3knienie szpiku) leczonych interferonem alfa oraz pacjentami chorymi na przewlek\u0142\u0105 bia\u0142aczk\u0119 szpikow\u0105 (PBSz) leczonymi inhibitorami kinazy tyrozynowej i sprawdzenie czy poszczeg\u00f3lne skutki uboczne leczenia mog\u0105 sprzyja\u0107 wyst\u0119powaniu objaw\u00f3w depresyjnych.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Metoda<\/jats:title>\n                    <jats:p>W badaniu wzi\u0119\u0142o udzia\u0142 175 doros\u0142ych pacjent\u00f3w chorych na MPN (n=84) lub PBSz (n=91) pozostaj\u0105cych w trakcie leczenia interferonem alfa lub IKT przez okres minimum 3 miesi\u0119cy. W badaniu u\u017cyto: Kwestionariusz Davida Goldberga (GHQ-28), Czterowymiarowy Kwestionariusz 4DSQ oraz ankiet\u0119 w\u0142asn\u0105.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Wyniki<\/jats:title>\n                    <jats:p>Wynik \u015brednio i mocno podwy\u017cszony na skali depresji uzyska\u0142o w przypadku chorych na MPN prawie 40% badanych, a w przypadku chorych na PBSz niemal 20% pacjent\u00f3w. Analiza nie wykaza\u0142a istotnie statystycznych r\u00f3\u017cnic pomi\u0119dzy kobietami i m\u0119\u017cczyznami. Skurcze i b\u00f3le mi\u0119\u015bni (\u03b2=0.196, p=0.013), nudno\u015bci i niestrawno\u015b\u0107 (\u03b2=0,191, p=0,007), m\u0119czliwo\u015b\u0107 (\u03b2=0,136, p=0,053), b\u00f3le ko\u015bci i staw\u00f3w (\u03b2=0,159, p=0,038) oraz biegunka (\u03b2=0,138, p=0,050) by\u0142y skutkami ubocznymi, kt\u00f3re wp\u0142ywa\u0142y na mo\u017cliwo\u015b\u0107 rozwoju objaw\u00f3w depresyjnych w obu grupach. Wsp\u00f3lnym predyktorem wyst\u0119powania depresyjnych by\u0142a liczba skutk\u00f3w ubocznych oraz rodzaj choroby i wiek. Im osoba by\u0142a starsza tym wi\u0119ksze by\u0142o nasilenie symptom\u00f3w depresyjnych.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Wnioski<\/jats:title>\n                    <jats:p>Pomi\u0119dzy pacjentami chorymi na PBSz i MPN wyst\u0119puj\u0105 istotne r\u00f3\u017cnice w zakresie wyst\u0119powania depresji. Poszczeg\u00f3lne skutki uboczne leczenia interferonem alfa oraz IKT maj\u0105 wp\u0142yw na wyst\u0119powanie objaw\u00f3w depresyjnych. Nie potwierdzono zale\u017cno\u015bci pomi\u0119dzy leczeniem interferonem a rozwojem depresji.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.12740\/pp\/onlinefirst\/202763","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T12:59:56Z","timestamp":1750165196000},"page":"259-274","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of depressive symptoms between patients with myeloproliferative neoplasms without the Philadelphia chromosome treated with interferon alpha and patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors"],"prefix":"10.12740","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3173-8513","authenticated-orcid":false,"given":"Katarzyna","family":"Gibek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Sacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5036","published-online":{"date-parts":[[2026,4,30]]},"container-title":["Psychiatria Polska"],"original-title":["Por\u00f3wnanie objaw\u00f3w depresyjnych mi\u0119dzy chorymi na nowotwory mieloproliferacyjne bez chromosomu\nPhiladelphia leczonymi interferonem alfa a chorymi na PBSz leczonymi inhibitorami kinazy tyrozynowej"],"link":[{"URL":"https:\/\/www.psychiatriapolska.pl\/pdf-202763-127633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.psychiatriapolska.pl\/pdf-202763-127633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T10:48:43Z","timestamp":1780829323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.psychiatriapolska.pl\/Comparison-of-depressive-symptoms-between-patients-with-myeloproliferative-neoplasms,202763,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":0,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"alternative-id":["202763"],"URL":"https:\/\/doi.org\/10.12740\/pp\/onlinefirst\/202763","relation":{},"ISSN":["0033-2674","2391-5854"],"issn-type":[{"value":"0033-2674","type":"print"},{"value":"2391-5854","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]}}}